Crossmark

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study

Crossref DOI link: https://doi.org/10.1186/s40478-021-01305-4

Published Online: 2022-01-03

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiguet-Jiglaire, Carine

Boissonneau, Sebastien

Denicolai, Emilie

Hein, Victoria

Lasseur, Romain

Garcia, Josep

Romain, Sylvie

Appay, Romain

Graillon, Thomas

Mason, Warren

Carpentier, Antoine F.

Brandes, Alba A.

Ouafik, L.’Houcine

Wick, Wolfgang

Baaziz, Ania

Gigan, Julien P.

Argüello, Rafael J.

Figarella-Branger, Dominique

Chinot, Olivier

Tabouret, Emeline https://orcid.org/0000-0002-4031-2178
Funding

Funding for this research was provided by:

ANR (ANR-20-CE-CE14-0028-01)

ARC

Canceropôle PACA

ARTC-sud
License Information

Text and Data Mining valid from 2022-01-03

Version of Record valid from 2022-01-03
More Information

Article History

Received: 8 November 2021

Accepted: 17 December 2021

First Online: 3 January 2022

Declarations

:

: All patients were required to give written informed consent before enrollment. The protocol was approved by the applicable independent ethics committees and institutional review boards. The study adhered to the principles of the Declaration of Helsinki and the Guidelines for Good Clinical Practice.

: Not applicable.

: The authors declare no potential conflicts of interest apart Josep Garcia who is employed by Roche ®.

Document is current

Any future updates will be listed below